ERBB2 gene amplification and receptor over-expression are causally linked to oncogenesis in ∼20% of breast cancers and define a molecular breast cancer subtype characterized by an adverse clinical outcome3, 4, 5. This evidence concerns the gene ERBB2 and breast carcinoma.